Literature DB >> 33425684

Nicotinic cholinergic system and COVID-19: In silico evaluation of nicotinic acetylcholine receptor agonists as potential therapeutic interventions.

Nikolaos Alexandris1, George Lagoumintzis1,2, Christos T Chasapis1, Demetres D Leonidas3, Georgios E Papadopoulos3, Socrates J Tzartos4, Aristidis Tsatsakis5, Elias Eliopoulos6, Konstantinos Poulas1,2, Konstantinos Farsalinos1.   

Abstract

SARS-CoV-2 infection was announced as a pandemic in March 2020. Since then, several scientists have focused on the low prevalence of smokers among hospitalized COVID-19 patients. These findings led to our hypothesis that the Nicotinic Cholinergic System (NCS) plays a crucial role in the manifestation of COVID-19 and its severe symptoms. Molecular modeling revealed that the SARS-CoV-2 Spike glycoprotein might bind to nicotinic acetylcholine receptors (nAChRs) through a cryptic epitope homologous to snake toxins, substrates well documented and known for their affinity to the nAChRs. This binding model could provide logical explanations for the acute inflammatory disorder in patients with COVID-19, which may be linked to severe dysregulation of NCS. In this study, we present a series of complexes with cholinergic agonists that can potentially prevent SARS-CoV-2 Spike glycoprotein from binding to nAChRs, avoiding dysregulation of the NCS and moderating the symptoms and clinical manifestations of COVID-19. If our hypothesis is verified by in vitro and in vivo studies, repurposing agents currently approved for smoking cessation and neurological conditions could provide the scientific community with a therapeutic option in severe COVID-19.
© 2020 The Authors. Published by Elsevier B.V.

Entities:  

Keywords:  ACh, Acetylcholine; AChBP, Acetylcholine-binding protein; ARDS, acute respiratory distress syndrome; BLAST, Basic Local Alignment Search Tool; CHARMM, Chemistry at Harvard Macromolecular Mechanics; CNS, Central Nervous System; COVID-19; Cholinergic agonists; CoV, coronavirus; DCD, single precision binary FORTRAN; ECD, extracellular domain; HADDOCK, High Ambiguity Driven protein-protein DOCKing; HMGB1, High-mobility group protein 1; IL, Interleukin; Jak2, Janus kinases 2; LBD, Ligand Binding Domain; MD, Molecular Dynamics; MDS, Molecular Dynamics Simulations; MERS, Middle East Respiratory Syndrome; NAMD, Nanoscale Molecular Dynamics; NCBI, National Center for Biotechnology Information; NCS, Nicotinic Cholinergic System; NF-kB, nuclear factor kappa-light-chain-enhancer of activated B cells; NPT, constant number, pressure, energy; NVT, constant number, volume, energy; Nicotinic acetylcholine receptors; PDB, Protein Data Bank; PME, Particle Mesh Ewald; PRODIGY, PROtein binDIng enerGY prediction; PyMOL, Python Molecule; RBD, Receptor Binding Domain; RMSD, Root-mean-square deviation; SARS, Severe Acute Respiratory Syndrome; SARS-CoV-2; SARS-CoV-2 S1, SARS - 2 Spike Subunit 1 protein; STAT3, signal transducer and activator of transcription 3; STD NMR, Saturation Transfer Difference Nuclear Magnetic Resonance; Spike glycoprotein; TNF, Tumor Necrosis Factor; VMD, Visual Molecular Dynamics; lig, ligand; nAChRs, nicotinic acetylcholine receptors

Year:  2020        PMID: 33425684      PMCID: PMC7776751          DOI: 10.1016/j.toxrep.2020.12.013

Source DB:  PubMed          Journal:  Toxicol Rep        ISSN: 2214-7500


  15 in total

1.  A Tale of Two Twins: Discordant Presentation of COVID-19 in Identical Twins.

Authors:  Nicole Chan; Joseph I Berger; Alan Guo; Nirja Inamdar; Mark Samarneh
Journal:  Cureus       Date:  2022-06-02

Review 2.  Inflammatory reflex disruption in COVID-19.

Authors:  Khalil Hajiasgharzadeh; Mahdi Jafarlou; Behzad Mansoori; Narges Dastmalchi; Behzad Baradaran; Alireza Khabbazi
Journal:  Clin Exp Neuroimmunol       Date:  2022-04-29

3.  A computational study on hydroxychloroquine binding to target proteins related to SARS-COV-2 infection.

Authors:  V B Navya; M V Hosur
Journal:  Inform Med Unlocked       Date:  2021-08-23

Review 4.  COVID-19 pandemic and alcohol consumption: Impacts and interconnections.

Authors:  Daniela Calina; Thomas Hartung; Ileana Mardare; Mihaela Mitroi; Konstantinos Poulas; Aristidis Tsatsakis; Ion Rogoveanu; Anca Oana Docea
Journal:  Toxicol Rep       Date:  2021-03-10

5.  Use of ivermectin in the treatment of Covid-19: A pilot trial.

Authors:  Henrique Pott-Junior; Mônica Maria Bastos Paoliello; Alice de Queiroz Constantino Miguel; Anderson Ferreira da Cunha; Caio Cesar de Melo Freire; Fábio Fernandes Neves; Lucimar Retto da Silva de Avó; Meliza Goi Roscani; Sigrid De Sousa Dos Santos; Silvana Gama Florêncio Chachá
Journal:  Toxicol Rep       Date:  2021-03-09

Review 6.  The Cholinergic and ACE-2-Dependent Anti-Inflammatory Systems in the Lung: New Scenarios Emerging From COVID-19.

Authors:  Martina Di Maro; Mauro Cataldi; Mariarosaria Santillo; Martina Chiurazzi; Simona Damiano; Barbara De Conno; Antonio Colantuoni; Bruna Guida
Journal:  Front Physiol       Date:  2021-05-13       Impact factor: 4.566

7.  Nicotinic receptors as SARS-CoV-2 spike co-receptors?

Authors:  Valérian Dormoy; Jeanne-Marie Perotin; Philippe Gosset; Uwe Maskos; Myriam Polette; Gaëtan Deslée
Journal:  Med Hypotheses       Date:  2021-12-14       Impact factor: 1.538

8.  Could Small Neurotoxins-Peptides be Expressed during SARS-CoV-2 Infection?

Authors:  Concetta Cafiero; Alessandra Micera; Agnese Re; Loredana Postiglione; Andrea Cacciamani; Beniamino Schiavone; Giulio Benincasa; Raffaele Palmirotta
Journal:  Curr Genomics       Date:  2021-12-31       Impact factor: 2.236

9.  Sinus bradycardia is associated with poor outcome in critically ill patients with COVID-19 due to the B.1.1.7 Lineage.

Authors:  Athanasios Chalkias; Ioannis Pantazopoulos; Nikolaos Papagiannakis; Anargyros Skoulakis; Eleni Laou; Konstantina Kolonia; Nicoletta Ntalarizou; Konstantinos Tourlakopoulos; Athanasios Pagonis; Christos Kampolis; Luis García De Guadiana Romualdo; Dimitrios Ragias; Jesper Eugen-Olsen; Konstantinos Gourgoulianis; Eleni Arnaoutoglou
Journal:  Toxicol Rep       Date:  2021-07-08

10.  Tobacco smoking and severity of COVID-19: Experience from a hospital-based prospective cohort study in Lyon, France.

Authors:  Mitra Saadatian-Elahi; Sélilah Amour; Christelle Elias; Laetitia Henaff; Cédric Dananché; Philippe Vanhems
Journal:  J Med Virol       Date:  2021-08-10       Impact factor: 20.693

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.